Effects of gonadotropin-releasing hormone agonists on infertility

Comparison the effects of ovulation triggering drugs including gonadotropin-releasing hormone agonists and human chorionic gonadotropin on pregnancy rate in infertile women undergoing intrauterine insemination

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015011920408N4

Enrollment

110

Registered

2017-01-14

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the genitourinary system. Non inflammatory disorders of female genital tract

Interventions

Intervention 1: Intervention 1: Clomiphene citrate (Tab, 50 mg, oral, three times a day, on days 3-7 of menstrual cycles, Aburaihan company, Iran) plus recombinant FSH (Ampule 75 IU, SC, twice daily f

Treatment - Drugs

Intervention 1: Clomiphene citrate (Tab, 50 mg, oral, three times a day, on days 3-7 of menstrual cycles, Aburaihan company, Iran) plus recombinant FSH (Ampule 75 IU, SC, twice daily for 3 days on day

Intervention 2: Clomiphene (Tab, 50 mg, oral, three times a day, on days 3-7 of menstrual cycles, Aburaihan company, Iran) plus plus recombinant FSH (Ampule 75 IU, SC, twice daily for 3 days on day ei

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Infertile women at age of =35 years; normal early follicular FSH; no medication in previous cycle; both tubes patency; presence of ovaries; no endometriosis; mild male subferiltiy. Exclusion criteria: Medical diseases; severe male infertility; poor response ovaries; peri-tubal adhesion.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy rate. Timepoint: Two weeks after intrauterine insemination. Method of measurement: Laboratory kits.	—

Secondary

Measure	Time frame
Ovarian hyper stimulation syndrome rate. Timepoint: Human chorionic gonadotropin injection until two weeks. Method of measurement: Ultrasonography.;Ovarian hyper stimulation syndrome rate. Timepoint: From gonadotropin realesing hormone agonist injection day until two weeks. Method of measurement: Ultrasonography.;Estradiol levels. Timepoint: 12 and 36 hours post ovulation. Method of measurement: Laboratory kits.;Fullicular stimulating Hormone levels. Timepoint: 12 and 36 hours post ovulation. Method of measurement: Laboratory kits.	—

Measure

Time frame

Ovarian hyper stimulation syndrome rate. Timepoint: Human chorionic gonadotropin injection until two weeks. Method of measurement: Ultrasonography.;Ovarian hyper stimulation syndrome rate. Timepoint: From gonadotropin realesing hormone agonist injection day until two weeks. Method of measurement: Ultrasonography.;Estradiol levels. Timepoint: 12 and 36 hours post ovulation. Method of measurement: Laboratory kits.;Fullicular stimulating Hormone levels. Timepoint: 12 and 36 hours post ovulation. Method of measurement: Laboratory kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Zamaniyan

Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical S

marziehzamaniyan@gmail.com+98 911 356 6650

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026